🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 27/11/2009 | 38,55 | 39,38 | 38,42 | 39,00 | -0,96% | 2,49% | 545.000 |
| 25/11/2009 | 39,13 | 39,68 | 39,11 | 39,38 | +0,82% | 1,46% | 906.500 |
| 24/11/2009 | 39,17 | 39,42 | 38,49 | 39,06 | -0,76% | 2,37% | 1.251.500 |
| 23/11/2009 | 38,96 | 39,73 | 38,66 | 39,36 | +2,13% | 2,75% | 1.437.200 |
| 20/11/2009 | 38,70 | 39,15 | 38,54 | 38,54 | -0,98% | 1,58% | 1.590.800 |
| 19/11/2009 | 39,55 | 39,77 | 38,71 | 38,92 | -1,49% | 2,68% | 2.345.500 |
| 18/11/2009 | 40,50 | 40,54 | 39,26 | 39,51 | -2,54% | 3,16% | 1.773.500 |
| 17/11/2009 | 40,05 | 40,60 | 39,71 | 40,54 | +0,10% | 2,22% | 2.227.400 |
| 16/11/2009 | 40,52 | 41,00 | 40,41 | 40,50 | -0,20% | 1,46% | 2.560.900 |
| 13/11/2009 | 40,79 | 41,05 | 40,45 | 40,58 | -0,64% | 1,47% | 1.982.100 |
| 12/11/2009 | 41,18 | 41,30 | 40,07 | 40,84 | -0,63% | 2,99% | 2.074.900 |
| 11/11/2009 | 40,65 | 41,75 | 40,65 | 41,10 | +1,01% | 2,71% | 4.134.300 |
| 10/11/2009 | 39,56 | 41,13 | 39,50 | 40,69 | +1,75% | 4,12% | 3.308.200 |
| 09/11/2009 | 39,22 | 40,00 | 39,07 | 39,99 | +1,96% | 2,37% | 2.685.800 |
| 06/11/2009 | 38,60 | 39,50 | 38,09 | 39,22 | +1,24% | 3,65% | 3.076.800 |
| 05/11/2009 | 36,94 | 38,75 | 36,92 | 38,74 | +5,01% | 4,95% | 3.799.000 |
| 04/11/2009 | 37,78 | 38,17 | 36,82 | 36,89 | -0,05% | 3,57% | 2.969.200 |
| 03/11/2009 | 36,12 | 37,25 | 36,04 | 36,91 | +2,10% | 3,35% | 3.042.500 |
| 02/11/2009 | 37,13 | 38,68 | 36,01 | 36,15 | +7,72% | 7,19% | 9.237.200 |
| 30/10/2009 | 33,73 | 34,80 | 33,55 | 33,56 | -0,86% | 3,71% | 3.917.100 |
| 29/10/2009 | 33,40 | 34,08 | 33,24 | 33,85 | +2,27% | 2,51% | 2.821.800 |
| 28/10/2009 | 33,60 | 34,66 | 33,09 | 33,10 | -0,81% | 4,67% | 3.756.200 |
| 27/10/2009 | 32,19 | 33,70 | 31,93 | 33,37 | +3,92% | 5,50% | 3.858.500 |
| 26/10/2009 | 32,45 | 32,67 | 31,83 | 32,11 | -1,20% | 2,59% | 2.589.900 |
| 23/10/2009 | 32,74 | 32,91 | 32,33 | 32,50 | -1,25% | 1,77% | 2.496.600 |
| 22/10/2009 | 32,90 | 33,19 | 32,82 | 32,91 | +0,03% | 1,12% | 1.981.300 |
| 21/10/2009 | 33,02 | 33,49 | 32,88 | 32,90 | -0,99% | 1,85% | 2.336.900 |
| 20/10/2009 | 34,46 | 34,58 | 32,99 | 33,23 | -4,59% | 4,61% | 2.524.400 |
| 19/10/2009 | 34,85 | 35,02 | 34,10 | 34,83 | -0,06% | 2,64% | 1.509.900 |
| 16/10/2009 | 35,25 | 35,45 | 34,74 | 34,85 | -1,16% | 2,01% | 2.254.100 |